Trevena (TRVN) says FDA informed it that data were not sufficient to support continuation of previously granted Breakthrough Therapy designation for oliceridine
Tweet Send to a Friend
Trevena (NASDAQ: TRVN) disclosed in an SEC filing:In February 2016, based on the preliminary evidence from Trevena’s (the “Company”) Phase ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
